

BioSpect

the business of Bio

24 years of leveraging the business of Bio
www.biospectrumindia.com

Stempeutics receives US patent for treatment of Osteoarthritis using Stempeucel®-OA

14 August 2026 | News

Stempeucel®-OA is marketed under the brands CiproStem by Cipla and StemOne by Alkem



Bengaluru-based Stempeutics Research, a group company of Manipal Education and Medical Group, has announced that the United States (US) Patent and Trademark Office (USPTO) has granted US Patent No. 12,661,377 for a treatment approach using its stem cell-based drug Stempeucel®-OA for osteoarthritis.

The patent covers an ultrasound-guided, intra-articular treatment involving a single dose of 25 million ex vivo expanded, pooled and cultured adult bone marrow-derived mesenchymal stromal cells (Stempeucel®-OA), administered before a single injection of mid-molecular-weight hyaluronic acid.

The therapy is intended to act at the cellular level, helping reduce inflammation and pain, improve joint function and support the preservation of cartilage quality in patients with Grade II and III knee osteoarthritis.

The patented invention also covers methods associated with increasing levels of anti-inflammatory markers and decreasing levels of disease-progression markers in individuals with osteoarthritis. The development addresses a significant and growing clinical need, with an estimated 48.4 million people in India living with knee osteoarthritis in 2021. As the condition can progressively affect mobility, physical function and quality of life, treatment approaches aimed at addressing the underlying disease process remain an important area of clinical research.

The company has filed more than 100+ patents and received over 60+ granted patents globally including US, Japan and EU.